June 18, 2021
Business News

CEL-SCI Announces the Closing of $31.7 Million Bought Deal Offering

VIENNA, Va.–()–CEL-SCI Corporation (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced the closing of the offering of 1,400,000 shares of its common stock at a price of $22.62 per share, for total gross proceeds of approximately $31.7 million, before deducting underwriting discounts and other offering expenses payable by the Company. Additionally, the Company has granted the underwriter a 30-day option to purchase up to 210,000 additional shares to cover over-allotments.

Kingswood Capital Markets, division of Benchmark Investments, LLC acted as sole book-running manager for the offering.

The shares of common stock described above were offered by CEL-SCI pursuant to a “shelf”…

Click here to view the original article.

Related Posts

You might also like ...

AON Splash Image
eCommerce Funding and Payments Leader Payability Hires VP of Growth Marketing
AON Splash Image
Arkema Announces a New Breakthrough Range of Renewable PVDF Grades for Lithium-Ion Batteries
Customers Bank Announces Promotions and New Hire in Accounting Department